AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment
AbCellera’s share price {$ABCL} climbed about 31% by mid-morning Monday after the biotech shared positive data from a mid-stage hot flashes trial that surpassed Wall Street's expectations. The biotech’s NK3R (neurokinin 3 receptor)-targeting antibody, known ...
AbCellera, a company listed on the Nasdaq under the ticker ABCL, has reported positive top-line results from the Phase 2 clinical trial of ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. This antibody is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms (VMS M-S), commonly known as hot flashes, experienced by menopausal women.
The trial met its primary efficacy endpoints by demonstrating statistically significant reductions in both the frequency and severity of VMS M-S at week 4, compared to the placebo group, following a single dose. Additionally, ABCL635 was observed to significantly improve sleep quality and overall patient perception of improvement, as measured by the patient global impression of change (PGI-C).
Brief written by urgent.news from Financial Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
